CN115003325A - 因子xi/xia抗体的药物制剂和剂量方案 - Google Patents

因子xi/xia抗体的药物制剂和剂量方案 Download PDF

Info

Publication number
CN115003325A
CN115003325A CN202080093971.9A CN202080093971A CN115003325A CN 115003325 A CN115003325 A CN 115003325A CN 202080093971 A CN202080093971 A CN 202080093971A CN 115003325 A CN115003325 A CN 115003325A
Authority
CN
China
Prior art keywords
seq
antibody
variable region
chain variable
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080093971.9A
Other languages
English (en)
Chinese (zh)
Inventor
D.A.弗里德霍尔姆
D.M.布鲁姆菲尔德
R.J.格拉斯普尔
J.E.弗里曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antos Therapeutics Co ltd
Original Assignee
Antos Therapeutics Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antos Therapeutics Co ltd filed Critical Antos Therapeutics Co ltd
Publication of CN115003325A publication Critical patent/CN115003325A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN202080093971.9A 2019-12-20 2020-12-18 因子xi/xia抗体的药物制剂和剂量方案 Pending CN115003325A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962951887P 2019-12-20 2019-12-20
US62/951,887 2019-12-20
PCT/US2020/066151 WO2021127525A1 (en) 2019-12-20 2020-12-18 Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies

Publications (1)

Publication Number Publication Date
CN115003325A true CN115003325A (zh) 2022-09-02

Family

ID=76478578

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080093971.9A Pending CN115003325A (zh) 2019-12-20 2020-12-18 因子xi/xia抗体的药物制剂和剂量方案

Country Status (9)

Country Link
US (1) US20230071973A1 (https=)
EP (1) EP4076511A4 (https=)
JP (2) JP2023507795A (https=)
KR (1) KR20220119090A (https=)
CN (1) CN115003325A (https=)
BR (1) BR112022012064A2 (https=)
CA (1) CA3161118A1 (https=)
IL (1) IL293367A (https=)
WO (1) WO2021127525A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024540435A (ja) * 2021-11-18 2024-10-31 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の投薬レジメン
TW202333789A (zh) * 2022-01-05 2023-09-01 大陸商上海邁晉生物醫藥科技有限公司 一種包含抗ＦＸＩ／ＦＸＩａ抗體的醫藥組成物及其用途
DE102022116219A1 (de) * 2022-06-29 2024-01-04 St. Jude Medical, Cardiology Division, Inc. Kandidatenscreening für eine Zieltherapie

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129379A1 (en) * 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
CN107922505A (zh) * 2015-06-26 2018-04-17 诺华股份有限公司 凝血因子xi抗体及使用方法
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8476239B2 (en) * 2005-12-20 2013-07-02 Bristol-Myers Squibb Company Stable protein formulations
CN106038481A (zh) * 2007-06-28 2016-10-26 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
AU2017383232B2 (en) * 2016-12-23 2024-09-12 Novartis Ag Factor XI antibodies and methods of use
US20190367636A1 (en) * 2017-01-19 2019-12-05 Bayer Pharma Aktiengesellschaft Novel stable formulation for fxia antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
JP2024540435A (ja) * 2021-11-18 2024-10-31 アントス セラピューティクス， インコーポレイテッド 第ＸＩ／ＸＩａ因子抗体の投薬レジメン

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100129379A1 (en) * 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
CN105073775A (zh) * 2013-02-08 2015-11-18 诺华股份有限公司 抗-il-17a抗体及其在治疗自身免疫性和炎性病症中的用途
CN107922505A (zh) * 2015-06-26 2018-04-17 诺华股份有限公司 凝血因子xi抗体及使用方法
CN108136015A (zh) * 2015-08-20 2018-06-08 艾伯维施特姆森特克斯有限责任公司 抗dll3抗体药物缀合物以及使用方法
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法

Also Published As

Publication number Publication date
KR20220119090A (ko) 2022-08-26
BR112022012064A2 (pt) 2022-08-30
JP2023507795A (ja) 2023-02-27
EP4076511A4 (en) 2024-02-14
WO2021127525A1 (en) 2021-06-24
EP4076511A1 (en) 2022-10-26
IL293367A (en) 2022-07-01
JP2026048712A (ja) 2026-03-17
US20230071973A1 (en) 2023-03-09
CA3161118A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
TWI820482B (zh) 凝血因子xi抗體及使用方法
KR102576012B1 (ko) 고농도 항-c5 항체 제형
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP7003354B2 (ja) 遺伝性血管性浮腫の発作を治療するための血漿カリクレイン阻害薬およびその用途
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
KR20250037482A (ko) 항-인자 xi/인자 xia 항체와의 조합 요법
CN118302196A (zh) 因子XI/XIa抗体的给药方案
RU2847356C2 (ru) Антитела к фактору xi и способы их применения
EA045920B1 (ru) Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека
BR112017027778B1 (pt) Anticorpo anti-fxi e/ou anti-fxia ativado isolado, usos do mesmo, composição farmacêutica, medicamento, sequência de ácido nucleico, e vetor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination